{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=37",
    "query": {
      "intervention": "Cell Therapy",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 12467,
    "total_pages": 1247,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T20:12:33.267Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01390402",
      "title": "Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "NK cell infusion:",
          "type": "PROCEDURE"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic related Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 6,
      "start_date": "2012-01",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-02-03",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01390402"
    },
    {
      "nct_id": "NCT00606437",
      "title": "Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Myeloma",
        "Leukemia",
        "Myelodysplasia",
        "Solid Tumors",
        "Hodgkin's Disease",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Total Body Irradiation with Fludarabine in UCB Transplants",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "14 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2005-09",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2014-05-16",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00606437"
    },
    {
      "nct_id": "NCT02270645",
      "title": "Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nodular Basal Cell Carcinoma",
        "Superficial Basal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "595/1064 multiplex laser",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2014-10",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2018-10-02",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02270645"
    },
    {
      "nct_id": "NCT04091672",
      "title": "RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Full-thickness Skin Defects",
        "Degloving Injuries",
        "Crush Injuries",
        "Laceration of Skin",
        "Surgical Wound",
        "Skin Cancer",
        "Cellulitis",
        "Infection",
        "Necrotizing Fasciitis",
        "Gun Shot Wound"
      ],
      "interventions": [
        {
          "name": "Control Intervention (Conventional Autograft)",
          "type": "PROCEDURE"
        },
        {
          "name": "Investigational Intervention (RECELL + more widely meshed autograft)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "Avita Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2020-03-02",
      "completion_date": "2023-02-02",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04091672"
    },
    {
      "nct_id": "NCT01975831",
      "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Colorectal Cancer",
        "Cervical Cancer",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2013-12-19",
      "completion_date": "2021-07-02",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01975831"
    },
    {
      "nct_id": "NCT00054795",
      "title": "Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Metastases, Neoplasm"
      ],
      "interventions": [
        {
          "name": "Motexafin Gadolinium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-05-08",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054795"
    },
    {
      "nct_id": "NCT00084695",
      "title": "Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Langerhans Cell Histiocytosis",
        "Fanconi Anemia",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Neuroblastoma",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 25,
      "start_date": "2003-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084695"
    },
    {
      "nct_id": "NCT03460977",
      "title": "A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)",
        "Small Cell Lung Cancer (SCLC)",
        "Follicular Lymphoma (FL)"
      ],
      "interventions": [
        {
          "name": "Mevrometostat (PF-06821497)",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 453,
      "start_date": "2018-04-17",
      "completion_date": "2029-07-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 45,
      "location_summary": "Tucson, Arizona • Anaheim, California • Duarte, California + 22 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03460977"
    },
    {
      "nct_id": "NCT00488982",
      "title": "Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel and GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 125,
      "start_date": "2007-04",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2019-11-20",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00488982"
    },
    {
      "nct_id": "NCT02453282",
      "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small-Cell Lung Carcinoma NSCLC"
      ],
      "interventions": [
        {
          "name": "MEDI4736 (Durvalumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4736 (Durvalumab)+Tremelimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel + Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed + Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed + Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1118,
      "start_date": "2015-07-21",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-26T20:12:33.267Z",
      "location_count": 35,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02453282"
    }
  ]
}